why on earth has this exciting pharma company been ignored her for the last 3.5 years? ...... lots has happened in that time, generally for the better on the longer view ..... from a purely chart point of view, the 200 mda is rising quite steadily, with sp recovering well after a sharp fall, and now, after a brief tease below, is therefore probably worth buying on that basis alone.

From memory, Shares mag was also quite excited about this stock a week or two back, even though that medium has supported some classic stinkers in its time

originally took profit, but bought back in this morning ...... this has to be a winner, which is more than one can say for so many of the "scallywag" stocks like GOO and CHP and VOG and SEY (we won't mention SEO!), all of which I also hold (not SEO!), on the basis that just perhaps one or two will come up with sweeties.

Perhaps time to revisit this "real" pharma company ...... Rumours have long circulated the market about consolidation in this sector, and SHP would certainly make a tasty morsel with its track record and pipeline ...... all time high was about 15.00 but that was in 2001 (I think), so probably of little relevance, except questionably to point to a possible buy-out level

gob and wallet have now joined up!

Cynic you are so funny sometimes, hows your pain threshold? still a good trade in my opinion.
good luck
regards

position is in the money, so at the mo, am a happy bunny (boiler) ...... to answer the question to which i think you allude ..... some stocks i hold a relatively long time; others i trade within a few weeks or even days

not only, as "stolen" from the Indie ...... Shire is expected to get the green light in a matter of days from US regulators to launch Mesavance, its biggest new drug in years ....... but the company is also a likely candidate for t/o at some time, perhaps sooner rather than later

sp rather gone to sleep ..... 200 dma left miles behind ... sp currently "teasing" just below 25 dma ..... rsi shows neutra/oversold ...... trend still steadily upwards



red = 25 dma
green = 50 dma

yet another quality stock that you guys seem to ignore ...... confess to feeling a bit like the prophet in his own land (only Cassandra alter ego when suggesting gloom and doom!) ..... top notch results just abnnounced ..... sp just heading north through 25 dma (potential resistance) ...... rsi neutral to o'sold .... company still a potential t/o target

will be interesting to see what the press and analysts make of these results, but i would hope (reasonably expect) that they are also very positive .... would be nice to see sp holding above that psychological 1100 level

Doing nicely again today Cynic. Could be those vague takeover rumours may have some imminent substance to them

Great news - to compensate (me) for the awful news on AZM: Vyvanse has been given FDA approval. The chart is just whizzing!

I think from now on it's dealing in CFDs for me, which is what I finally plucked up the courage to do with SHP - gives one very much more flexibility.

SHP figures towards bottom end of market forecasts so sp being whacked a bit ...... however, in recent days there has been the Phase III success of one of SHP's drugs and i daresay any weakness in sp might make the company even more tempting as a t/o target

It was a bit of a shock initially, I agree, but sp picking up now. Analyst meeting and webcast at 14:00 - will be interesting to hear what questions are raised.

is this worth buying now?

in my opinion, yes ...... SHP is a very well established and proven pharma company with real products

i've just bought - sp will pick up well - expect good profit on this one now

in fact easy money!

hard to justify the grumpy reaction by sp ..... prob mainly short term profit taking, though i suppose the CEO is not jumping up and won with excitement at the prospects - but all the better for it imo


Shire Pharmaceuticals Plc. posted first-quarter sales of $702 million, up 33 percent, and slightly ahead of expectations, with the company reaffirming its financial guidance for this year and predicting positive growth through to 2010.

Analysts' consensus in a Thomson poll was for sales of 700 million in the quarter.

Diluted EPS was 22.7 cents, compared with 21.3 cents in the previous year.

The company also said its Vyvanse ADHD product would generate sales at 'the lower end' of the $350 million to $400 million range.

Vyvanse achieved a 6.9 percent share of the U.S. ADHD market in the quarter, with sales of $54.4 million, the company said.

CEO Matthew Emmens said: 'It's been a good start to the year with sales growth from new and established products achieving our expectations.'

Emmens affirmed the company's previous financial guidance for the year and predicted positive revenue growth through to 2010.

is this worth buying now as its much lower since i last asked.....glad i didny buy at the time

SHP certain to be whacked open along with other pharmas due to "proposals will include average price cuts of about 5 percent for existing medicines, however this will be sweetened by assurances of more rapid and widespread uptake by the National Health Service of higher-priced new treatments".

not yet on view, but clearly from the reaction SHP's numbers were at lesat very satisfactory ...... this could really fly as the heavy short selling (surely, judging by recent sp movement) is forced to close